Suppr超能文献

β-乳球蛋白的微纳米结构作为生物活性化合物载体:体外研究。

β-lactoglobulin micro- and nanostructures as bioactive compounds vehicle: In vitro studies.

机构信息

CEB - Centre of Biological Engineering, University of Minho, Campus de Gualtar, 5710-057 Braga, Portugal.

CBQF - Centro de Biotecnologia e Química Fina, Escola Superior de Biotecnologia, Universidade Católica Portuguesa/Porto, Porto 4169-005, Portugal.

出版信息

Food Res Int. 2020 May;131:108979. doi: 10.1016/j.foodres.2020.108979. Epub 2020 Jan 7.

Abstract

β-Lactoglobulin (β-Lg) is known to be capable to bind hydrophilic and hydrophobic bioactive compounds. This research aimed to assess the in vitro performance of β-Lg micro- (diameter ranging from 200 to 300 nm) and nano (diameter < 100 nm) structures associated to hydrophilic and hydrophobic model compounds on Caco-2 cells and under simulated gastrointestinal (GI) conditions. Riboflavin and quercetin were studied as hydrophilic and hydrophobic model compounds, respectively. Cytotoxicity experiment was conducted using in vitro cellular model based on human colon carcinoma Caco-2 cells. Moreover, the digestion process was simulated using the harmonized INFOGEST in vitro digestion model, where samples were taken at each phase of digestion process - oral, gastric and intestinal - and characterized in terms of particle size, polydispersity index (PDI), surface charge by dynamic light scattering (DLS); protein hydrolysis degree by 2,4,6-trinitrobenzene sulfonic acid (TNBSA) assay and native polyacrylamide gel electrophoresis; and bioactive compound concentration. Caco-2 cell viability was not affected up to 21 × 10 mg mL of riboflavin and 16 × 10 mg mL quercetin on β-Lg micro- and nanostructures. In the oral phase, β-Lg structures' particle size, PDI and surface charge values were not changed comparing to the initial β-Lg structures (i.e., before being subjected to in vitro GI digestion). During gastric digestion, β-Lg structures were resistant to proteolytic enzymes and to acid environment of the stomach - confirmed by TNBSA and native gel electrophoresis. In vitro digestion results indicated that β-Lg micro- and nanostructures protected both hydrophilic and hydrophobic compounds from gastric conditions and deliver them to target site (i.e., intestinal phase). In addition, β-Lg structures were capable to enhance riboflavin and quercetin bioaccessibility and bioavailability potential compared to bioactive compounds in their free form. This study indicated that β-Lg micro- and nanostructures were capable to enhance hydrophilic and hydrophobic compounds bioavailability potential and they can be used as oral delivery systems.

摘要

β-乳球蛋白(β-Lg)已知能够结合亲水性和疏水性生物活性化合物。本研究旨在评估β-Lg 微(直径 200-300nm)和纳米(直径<100nm)结构与亲水性和疏水性模型化合物在 Caco-2 细胞上的体外性能,并在模拟胃肠道(GI)条件下进行评估。核黄素和槲皮素分别作为亲水性和疏水性模型化合物进行研究。使用基于人结肠癌细胞 Caco-2 的体外细胞模型进行细胞毒性实验。此外,使用协调的 INFOGEST 体外消化模型模拟消化过程,在消化过程的各个阶段(口腔、胃和肠道)取样,并通过动态光散射(DLS)测量粒径、多分散指数(PDI)、表面电荷;通过 2,4,6-三硝基苯磺酸(TNBSA)测定法和天然聚丙烯酰胺凝胶电泳测定蛋白质水解程度;以及生物活性化合物浓度。在β-Lg 微纳米结构上,核黄素和槲皮素的浓度高达 21×10mg mL 和 16×10mg mL 时,Caco-2 细胞活力不受影响。在口腔阶段,与初始β-Lg 结构(即在进行体外 GI 消化之前)相比,β-Lg 结构的粒径、PDI 和表面电荷值没有变化。在胃消化过程中,β-Lg 结构能够抵抗蛋白酶和胃的酸性环境 - 通过 TNBSA 和天然凝胶电泳得到证实。体外消化结果表明,β-Lg 微纳米结构能够保护亲水性和疏水性化合物免受胃条件的影响,并将它们递送到靶部位(即肠道阶段)。此外,与游离形式的生物活性化合物相比,β-Lg 结构能够增强核黄素和槲皮素的生物利用度和生物利用潜力。本研究表明,β-Lg 微纳米结构能够增强亲水性和疏水性化合物的生物利用潜力,可作为口服给药系统。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验